Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to buy right now. On December 16, Bank of America analyst Jason Gerberry lowered the firm’s price target on Pfizer to $27 from $28 while keeping a Neutral rating on the shares. Pfizer’s 2026 guidance revealed a steeper erosion of its COVID-19 franchise than previously projected, leading the firm to trim its near-term financial forecasts. The focus has now shifted to the company’s obesity strategy; investors are awaiting trial results from the recently acquired Metsera assets to determine if they can successfully carve out a unique position in the high-growth weight-loss market.
Additionally, on December 17, Pfizer and Astellas announced positive topline results from the Phase 3 EV-304 trial (KEYNOTE-B15). The study showed that the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) significantly improved both event-free survival and overall survival when used as a perioperative treatment (before and after surgery) for patients with muscle-invasive bladder cancer/MIBC. This trial specifically focused on patients eligible for cisplatin-based chemotherapy, the current standard of care.
The trial also met its secondary endpoint of pathologic complete response rate, showing a statistically significant improvement over traditional neoadjuvant chemotherapy. These findings, combined with earlier results from the EV-303 trial, position the PADCEV and Keytruda combination as a potential platinum-free standard of care for MIBC patients, regardless of their eligibility for cisplatin. Currently, bladder cancer is diagnosed in over 614,000 patients globally each year, with MIBC accounting for ~30% of those cases.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
